<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221106056413N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-24</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of platelet-rich plasma injection in treatment of stress urinary incontinence.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effectiveness of pelvic floor biofeedback combined with autologous platelet-rich plasma injection in comparison to biofeedback as a monotherapy in rehabilitation of women with stress urinary incontinence.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66729</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible candidates to enter the study were assigned by random allocation using block randomization method. 48 recruited individuals were randomly assigned to one of the two groups of (intervention pelvic biofeedback and platelet rich plasma injection) and a control group (pelvic biofeedback), which will use block randomization with different block sizes. The size of the blocks will be a multiple of 2 and a divisor of 48 (2, 4, and 6). Initially, the block sizes are chosen randomly. Then for each block, different permutations are randomly determined by the Randomization Allocation Software. In each block, the number of people in the groups is equal, and blinding is used to not reveal the permutations in the last people of each block, Blinding description: In this study, patients will not know about how they are grouped and the details of the interventions performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stress urinary incontinence.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 24 patients undergoing pelvic floor muscle rehabilitation treatment as 35-minute sessions, once a week, including 20 minutes of electrical stimulation with a vaginal probe with biphasic alternating current settings with a frequency of 5 Hz and a pulse width of 300 microseconds and current intensity from 1 to 100 The milliampere is adjusted to the level tolerated by the patient. Then 15 minutes of biofeedback with pelvic floor rehabilitation protocol will be performed for the patient in 4 weekly sessions (one session per week) for one month. In between sessions, the patient should perform Kegel exercises 6 times a day. In this group, after 4 sessions of pelvic rehabilitation, one shot of platelet-rich plasma in the anterior 1/3 wall of the vagina is performed. Three shots of platelet-rich plasma are performed at 4-week intervals. Before performing the procedure, a full blood test will be performed for the patients for platelet count, prothrombin time and check liver enzymes to rule out liver diseases, and a complete urine test. Then the injection process will be explained to the patients and patients with the following abnormalities will be excluded from the trial: 1- Platelet disorders 2- Thrombocytopenia 3- Hypofibrinogenemia 4- Patients who are not hemodynamically stable 5- Acute/chronic infection 6- Chronic liver disease 7- Patients who use anticoagulants 8- Malignancy. Eligible patients will be referred to the pain and rehabilitation clinic, and after obtaining informed consent from the patients, two 10 ml samples of blood will be taken, and after centrifugation, two 5 ml samples of platelet-rich plasma will be prepared for administration. Gel-based Royagen kits will be used to prepare platelet-rich plasma. The procedure is done with the patient placed in the lithotomy position, the desired area will be numbed with local anesthesia, and the injection process will be performed under sterile conditions. The prepared plasma will be injected using a 27G needle in the anterior 1/3 of the vaginal wall around the middle urethra, which is located about 1 cm behind the urethra, with a depth of 1.5 cm (2 ml of the solution in Behind the urethra and 1.5 ml on both sides of the urethra at 11, 12 and 1 clocks). This procedure will be repeated every 4 weeks for 3 months. Intervention 2: Control group: 24 patients will undergo pelvic floor muscle rehabilitation treatment as 35-minute sessions, once a week, including 20 minutes of electrical stimulation with a vaginal probe with biphasic alternating current settings with a frequency of 5 Hz and a pulse width of 300 microseconds and current intensity from 1 to 100 The milliampere is adjusted to the level tolerated by the patient. Then 15 minutes of biofeedback with pelvic floor rehabilitation protocol will be performed for the patient in 4 weekly sessions (one session per week) for one month. In between sessions, the patient should perform Kegel exercises 6 times a day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tayebeh Sadat Salehi Rihani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, East 14th Ave., Sabari Blvd., Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956819173</zip>
        <telephone>+98 21 2645 2587</telephone>
        <email>tayebe.sadat.s.r@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tayebeh Sadat Salehi Rihani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, East 14th Ave., Sabari Blvd., Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956819173</zip>
        <telephone>+98 21 2645 2587</telephone>
        <email>tayebe.sadat.s.r@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with clinical symptoms of urinary incontinence.
Age 35-55
patients opting for non-surgical management.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Stage&gt;II prolapse
Cervical dysplasia and malignancy
Recurrent urinary tract infection
Pelvic reconstruction surgery
Pregnancy
Abnormal uterine bleeding
Anti-platelet drug medication
Psychological disorders
History of surgery due to urinary incontinence
Uncontrolled diabetes
Neurogenic urinary incontinence
Urge urinary incontinence</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N39.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Stress incontinence (female) (male)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 24 patients undergoing pelvic floor muscle rehabilitation treatment as 35-minute sessions, once a week, including 20 minutes of electrical stimulation with a vaginal probe with biphasic alternating current settings with a frequency of 5 Hz and a pulse width of 300 microseconds and current intensity from 1 to 100 The milliampere is adjusted to the level tolerated by the patient. Then 15 minutes of biofeedback with pelvic floor rehabilitation protocol will be performed for the patient in 4 weekly sessions (one session per week) for one month. In between sessions, the patient should perform Kegel exercises 6 times a day. In this group, after 4 sessions of pelvic rehabilitation, one shot of platelet-rich plasma in the anterior 1/3 wall of the vagina is performed. Three shots of platelet-rich plasma are performed at 4-week intervals. Before performing the procedure, a full blood test will be performed for the patients for platelet count, prothrombin time and check liver enzymes to rule out liver diseases, and a complete urine test. Then the injection process will be explained to the patients and patients with the following abnormalities will be excluded from the trial: 1- Platelet disorders 2- Thrombocytopenia 3- Hypofibrinogenemia 4- Patients who are not hemodynamically stable 5- Acute/chronic infection 6- Chronic liver disease 7- Patients who use anticoagulants 8- Malignancy. Eligible patients will be referred to the pain and rehabilitation clinic, and after obtaining informed consent from the patients, two 10 ml samples of blood will be taken, and after centrifugation, two 5 ml samples of platelet-rich plasma will be prepared for administration. Gel-based Royagen kits will be used to prepare platelet-rich plasma. The procedure is done with the patient placed in the lithotomy position, the desired area will be numbed with local anesthesia, and the injection process will be performed under sterile conditions. The prepared plasma will be injected using a 27G needle in the anterior 1/3 of the vaginal wall around the middle urethra, which is located about 1 cm behind the urethra, with a depth of 1.5 cm (2 ml of the solution in Behind the urethra and 1.5 ml on both sides of the urethra at 11, 12 and 1 clocks). This procedure will be repeated every 4 weeks for 3 months.</i_keyword>
      <i_keyword>Control group: 24 patients will undergo pelvic floor muscle rehabilitation treatment as 35-minute sessions, once a week, including 20 minutes of electrical stimulation with a vaginal probe with biphasic alternating current settings with a frequency of 5 Hz and a pulse width of 300 microseconds and current intensity from 1 to 100 The milliampere is adjusted to the level tolerated by the patient. Then 15 minutes of biofeedback with pelvic floor rehabilitation protocol will be performed for the patient in 4 weekly sessions (one session per week) for one month. In between sessions, the patient should perform Kegel exercises 6 times a day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Stress urinary incontinence. Timepoint: The effectiveness of platelet-rich plasma injection and pelvic floor biofeedback after 4 weekly sessions of biofeedback and 3 monthly sessions of PRP shots on women suffering from stress urinary incontinence. Method of measurement: International Consultation on Incontinence Questionnaire- Female Lower Urinary Tract Symptom  (ICIQ-FLUTS) long form and short form.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sexual Function. Timepoint: The effectiveness of platelet-rich plasma injection and pelvic floor biofeedback after 4 weekly sessions of biofeedback and 3 monthly sessions of PRP shots on sexual function of women suffering from stress urinary incontinence. Method of measurement: Female Sexual Function Index Pelvic incontinence Sexual Questionnaire-12.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: The effectiveness of platelet-rich plasma injection and pelvic floor biofeedback after 4 weekly sessions of biofeedback and 3 monthly sessions of PRP shots on quality of life of women suffering from stress urinary incontinence. Method of measurement: International Consultation on Incontinence Questionnaire- Quality of Life (ICIQ-QOL).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-30</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Physical &amp; Rehabilitation Medicine department, Faghihi hospital, Zand Street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
